Register
EU clears addition of cardiovascular benefits in labeling for canagliflozin |
Journal Updates
eMediNexus Coverage from: 
EU clears addition of cardiovascular benefits in labeling for canagliflozin
eMediNexus,  22 September 2018
remove_red_eye 707 Views
#Cardiology #Diabetes and Endocrinology #Pharmacist #Public Health

0 Read Comments                

 The European Commission has granted approval for the addition of positive cardiovascular outcomes data on the label of canagliflozin (Invokana, Vokanamet, Janssen). It can be now marketed for the prevention of major cardiovascular events as well as an oral hypoglycemic agent for adults with type 2 diabetes and a history of cardiovascular disease or at least two cardiovascular risk factors.
To continue reading this article
Sign in with Medtalks

Continue reading your article with a eMediNexus account.
Free Membership!